Table 1.
Radiation biomarkers used for studying the risk after different diagnostic procedures
| Procedure | Biomarkers | References |
|---|---|---|
| [18F] FDG PET/CT (∼5 mSv) | Proteomic marker (γ-H2AX foci) | May et al.93 |
| CCTA (∼8 mSv) | Proteomic marker (γ-H2AX foci) | Grudzenski et al.94 |
| CCTA (∼36.9 mSv) | Proteomic and genomic markers | Nguyen et al.28 |
| CCTA (∼11.4 mSv) | Proteomic marker (γ-H2AX foci) | Kuefner et al.95 |
| CCTA (∼6.4 mSv) | Proteomic marker (γ-H2AX foci) | Brand et al.54 |
| CT (∼6.3 mSv) | Proteomic marker (H2AX foci) | Rothkamm et al.38 |
| Invasive angiography (∼18.2 mSv) | Proteomic and genomic markers | Lee et al.39 |
| Invasive angiography (∼12 mSv) | Cytogenetic marker (MN assay) | Andreassi et al.96 |
| SPECT MPI (∼10.0 mSv) | Proteomic and genomic markers | Lee et al.39 |
PET, positron emission tomography; CT, computed tomography; CCTA, coronary computed tomography angiography; SPECT-MPI, single-photon emission computed tomography myocardial perfusion imaging; MN, micronucleus.